Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873210 | 1.00 | LMNA (0.58) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL31685335 | 0.89 | ADORA1 (0.48) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL23414481 | 0.88 | LMNA (0.59) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL30852235 | 0.88 | LMNA (0.59) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL8185392 | 0.87 | LMNA (0.58) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL21544852 | 0.87 | LMNA (0.58) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL6395695 | 0.87 | LMNA (0.58) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL8185399 | 0.87 | LMNA (0.58) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL27826042 | 0.87 | LMNA (0.58) | LMNAGMNNALDH1A1TP53NFKB1 | |
| SCHEMBL6393071 | 0.87 | TP53 (0.58) | LMNAGMNNALDH1A1TP53NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118019981-A | Methods for characterizing tumors | 蒙彼利埃大学医疗中心 | 2024-05-10 | — | — | CN | claimed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| CN-120082543-A | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119789852-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119604304-A | Recombinant RNA molecules comprising an untranslated region or a segment encoding spike protein from the Severe acute respiratory coronavirus 2 Omikovia strain | 葛兰素史克生物有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119375375-A | Method for detecting nucleotide, cap analogue and nucleic acid in vitro transcription product | 楷拓生物科技(苏州)有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-110573619-B | Nucleic acid products that inhibit TMPRSS6 gene expression and uses thereof | 赛伦斯治疗有限责任公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-118302524-A | High molecular weight modified dsRNA compositions | 纳诺索尔公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118019981-A | Methods for characterizing tumors | 蒙彼利埃大学医疗中心 | 2024-05-10 | — | — | CN | disclosed |
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | BAKER BRENDA F (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050032069-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004044245-A1 | OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1419247-A2 | METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS | Direvo Biotech AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003012100-A2 | METHOD FOR THE PRODUCTION OF NUCLEIC ACIDS CONSISTING OF STOCHASTICALLY COMBINED PARTS OF SOURCE NUCLEIC ACIDS | DIREVO BIOTECH AG (DE) | 2003-02-13 | — | — | WO | disclosed |
| EP-1281757-A1 | Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids | Direvo Biotech AG (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-6369040-B1 | INCORPORATING A COMPLEMENTARY SEQUENCES FOR HERPES, PAPILLOMA AND OTHER VIRUSES | ISIS PHARMACEUTICALS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6060592-A | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| WO-1995024185-A1 | NOVEL PYRIMIDINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | LMNA 1281/4885GMNN 774/4885ALDH1A1 4679/4885 |
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | LMNA 1281/4885GMNN 774/4885ALDH1A1 4679/4885 |
| US-20050032069-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | RNMT, RRBP1, G3BP1 | LMNA 1281/4885GMNN 774/4885ALDH1A1 4679/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | LMNA 240/4885GMNN 3368/4885ALDH1A1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.